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ABSTRACT 
In the past decade, a resurgence of serious illness due to group 
A Streptococcus has occurred. After declining in incidence for 
more than 50 years, acute rheumatic fever reappeared in the 
United States in several locations in the mid-1980s. In the late 
198Os, streptococcal toxic shock syndrome was recognized as 
an uncommon, but life-threatening form of infection manifested 
by shock and multiorgan failure. More recently, attention has 
focused on cases of streptococcal necrotizing fasciitis. The 
apparent global increase in the incidence of serious group A 
streptococcal disease syndromes has renewed interest in the 
epidemiology and pathogenesis of streptococcal infection and 
its sequelae. Recent studies implicate the dissemination of viru- 
lent strains, particularly the Ml and M3 serotypes, in the 
upswing of invasive disease. Pyrogenic exotoxins-the toxins 
responsible for scarlet fever-appear to play a pathogenic role 
in streptococcal toxic shock syndrome, perhaps through their 
T-cell stimulatoty activity as superantigens. Rheumatic fever 
has been associated with highly encapsulated strains of group 
A Streptococcus, and experimental studies have demonstrated 
that the hyaluronic acid capsule enhances the capacity of such 
strains both to colonize the pharynx and to cause invasive 
infection. 
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A cluster of six cases of necrotizing fasciitis due to group 
A Streptococcus (GAS) occurred in Gloucestershire, 
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England, during the winter and spring of 1994. In describ- 
ing this outbreak, a particularly creative reporter for a 
British tabloid coined the phrase “flesh-eating bacteria,” 
a graphic image that captured public interest in invasive 
group A streptococcal infection.’ Since that time, spo- 
radic cases of necrotizing fasciitis have been reported in 
the press worldwide. 
Even before these cases came to public attention, a 
number of reports in the medical literature over the past 
decade suggested an increased incidence of serious GAS 
disease. In this overview, new developments in clinical 
aspects of GAS disease are highlighted and findings from 
several recent studies of both the epidemiology and the 
basic biology of streptococcal disease pathogenesis are 
discussed to answer the following questions. Has the 
spectrum of GAS disease changed in recent years? If so, 
can the current trends be explained by changes in spe- 
cific bacterial virulence traits or in host susceptibility? 
Can new insights into disease pathogenesis suggest strate- 
gies to improve the outcome of patients with serious 
GAS disease? My interpretation of the available evidence 
is that there has been a real increase in the incidence of 
serious GAS disease in recent years. However, there is 
little support for the view that invasive syndromes like 
necrotizing fasciitis represent previously unknown man- 
ifestations of GAS infection. 
HISTORICAL PERSPECTIVE ON SEVERE 
GROUP A STREPTOCOCCAL DISEASE 
Several recent editorials and reviews of invasive strepto- 
coccal disease have pointed out that descriptions of seri- 
ous streptococcal infections can be found in the medical 
literature from centuries ago. For example, in the f&h 
century BC, Hippocrates wrote: “Many were attacked with 
erysipelas all over the body. When the exciting cause 
was a trivial accident or a very small wound.. . the 
erysipelas would quickly spread widely in all directions. 
Flesh, sinews, and bones fell away in large quantities.“2~3 
This vivid depiction describes a syndrome that we would 
probably diagnose today as necrotizing fasciitis. Although 
the microbiologic cause of disease in the patients 
observed by Hippocrates is not known, some strepto- 
coccal disease syndromes are sufficiently distinctive that 
descriptions are recognizable with reasonable certainty 
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in medical literature written long before the causative 
organism was identified. 
One such syndrome is scarlet fever. By the 16th cen- 
tury, scarlet fever had been distinguished from measles, 
another common childhood disease characterized by 
fever and rash (Table 1). In the 18th century, fatal or 
malignant scarlet fever was recognized in addition to the 
usual uncomplicated form that accompanied pharyngi- 
tis. Throughout this period, however, scarlet fever was 
generally considered to be a relatively benign childhood 
disease. The situation changed in the middle of the 19th 
century with massive epidemics of severe scarlet fever in 
many cities in Europe and North America.4 During the 
peak of the epidemic, 20,000 cases per year were diag- 
nosed in Great Britain, with case-fatality rates as high as 
30%. The epidemics tended to occur in 3- to 5-year cycles 
consistent with the introduction of a virulent strain into 
a susceptible population, with a high attack rate and 
severe illness; the subsequent development of immunity 
in the survivors; subsidence of the epidemic; and the 
introduction of a new virulent strain to begin a new epi- 
demic cycle. A similar phenomenon may be involved in 
the reemergence of serious streptococcal infections today 
In the 1870s Billroth and Pasteur independently iden- 
tified the causative agent of these infections in clinical 
specimens from patients with erysipelas and puerperal 
sepsis, respectively. Over the next 50 years, the organisms 
later classified as GAS or Streptococcus pyogenes were 
linked to a variety of human diseases, including pharyn- 
gitis, scarlet fever, skin and soft-tissue infections, and the 
unique postinfectious sequelae of poststreptococcal 
glomerulonephritis and acute rheumatic fever @RF). 
REAPPEARANCE OF ACUTE RHEUMATIC 
FEVER IN THE UNITED STATES 
For reasons not well understood, the incidence of ARE 
in North America and Europe declined throughout most 
of the 20th century. In the United States, the death rate 
from rheumatic fever decreased steadily from 1920 
onward, with an accelerated rate of decline coincident 
with introduction of antimicrobial prophylaxisj By 1980, 
it appeared that ARE was disappearing from the United 
States, although it remained endemic in many other areas 
Table 1. Historical Descriptions of Serious 
Group A Streptococcal Disease 
1553: lngrassia distinguished scarlet fever (“rossalia”) from measles 
1778: Johnstone classified scarlet fever as uncomplicated, 
associated with pharyngitis, or severe (“scarlatina maligna”) 
1830-I 880: Epidemics of fatal scarlet fever described in Dublin, 
London, New York 
1874, 1879: Billroth and Pasteur demonstrated streptococci in 
specimens from patients with erysipelas and puerperal sepsis 
of the world. In 1987, however, an outbreak of rheumatic 
fever was reported in the Salt Lake City area of Utah, 
where clinicians recorded 74 cases of ARF over an lS- 
month period, an eightfold increase over the incidence 
of ARE for the preceding decade.” During the next few 
years, similar outbreaks of ARE were reported from sev- 
eral locations around the United States.7-9 Several of these 
clusters of ARE including the Utah cases, were associ- 
ated with mucoid or highly encapsulated strains of GAS. 
STREPTOCOCCAL TOXIC SHOCK SYNDROME 
Around the same time, a few case reports and then a 
report of a larger series by Stevens and colleagues 
described a group of patients with severe GAS infections 
accompanied by shock and multiorgan failure.lO,” 
Because of similarities to staphylococcal toxic shock syn- 
drome (TSS), the syndrome was called streptococcal toxic 
shock-like syndrome. Manifestations include fever, 
hypotension, adult respiratory distress syndrome, renal 
failure, and coagulopathy (Table 2). In contrast to those 
with staphylococcal TSS, most patients with the strep- 
tococcal syndrome do not have a rash. Another important 
difference is that the majority of patients with strepto- 
coccal TSS have positive blood cultures, but bacteremia 
almost never occurs with staphylococcal TSS. Strepto- 
coccal TSS may be associated with primary infection at 
a variety of sites, most commonly necrotizing fasciitis, 
but also cellulitis, pneumonia, and other types of infec- 
tions. Mortality in several case series has been 30% or 
more.11-13 
INCREASING INCIDENCE OF INVASIVE GROUP A 
STREPTOCOCCAL DISEASE SYNDROMES 
Streptococcal TSS, necrotizing fasciitis, and GAS bac- 
teremia may be considered a set of overlapping clinical 
syndromes of invasive GAS disease (Figure 1). The major- 
ity of patients with streptococcal TSS are bacteremic, 
and 50 to 60% have necrotizing fasciitis. Of patients with 
necrotizing fasciitis, many but not all have bacteremia, 
streptococcal TSS, or both. Of patients with streptococcal 
Table 2. Clinical Features of Streptococcal 
Toxic Shock Syndrome 
Similar presentation to staphylococcal TSS: fever, hypotension, 
ARDS, renal failure 
Rash only occasionally present 
Most patients are bacteremic 
Associated focal infections: necrotizing fasciitis, cellulitis, pneumonia, 
others 
Mortality: 30%; requires aggressive supportive care (fluids, pressors, 
ventilator) 
TSS = Toxic shock syndrome: ARDS = Adult respiratory distress syndrome. 
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NECROTIZING 
BACTEREMIA 
Figure 1. Overlapping syndromes of invasive group A streptococcal 
infection. 
bacteremia, perhaps 10% have one or both of the other 
syndromes. Because reporting of invasive GAS infection 
has not been uniform for large population bases, it is dif- 
ficult to determine the precise incidence of these infec- 
tions over time, but several hospital-based surveys suggest 
an upward trend. 
A study, for example, from the Children’s Hospital 
in Denver showed a significant progressive increase in 
the rate of streptococcal bacteremia during the period 
1980 to 1990 over a baseline rate established in the 
1970s.14 Similarly, several groups reported an increased 
incidence of streptococcal necrotizing fasciitis associated 
with varicella in children.15-” Data from three hospitals 
in southern California showed a dramatic increase in such 
cases since 1990.” Such statistics raise the suspicion that 
there is something different about the streptococcal 
strains associated with these infections. 
M PROTEIN AS A VIRULENCE FACTOR 
Group A streptococcus elaborates a variety of surface 
molecules and extracellular products that may be impor- 
tant in pathogenesis (Table 3). M protein and capsular 
polysaccharide on the bacterial surface make GAS resis- 
tant to phagocytic killing. Secreted enzymes such as strep- 
tolysins 0 and S, protease, and hyaluronidase may 
facilitate the spread of infection by damaging cell mem- 
branes and producing tissue necrosis. Of these potential 
virulence factors, M protein has been studied in the most 
detail. 
Studies by Lancetield and others showed that GAS 
strains rich in M protein were virulent for experimental 
animals and were resistant to phagocytic killing in non- 
immune human blood.18 Later work by Fischetti, Beachey, 
Table 3. Partial List of Streptococcal Products That May Play a 
Role in Pathogenesis 




Pyrogenic exotoxins (erythrogenic toxins) 
M Protein and related molecules 
Hyaluronic acid capsule 
and others further delineated the basic structure of M 
protein.19-21 It is a coiled-coil dimeric protein arrayed in 
fibrils on the bacterial surface, with a relatively conserved 
carboxy-terminal region inserted into the cell wall and the 
amino terminus extending away from the cell (Figure 2). 
Opsonic antibodies are directed to the highly variable 
amino terminal portion of the protein. Two mechanisms 
have been proposed to explain how M protein renders 
GAS resistant to phagocytosis. Horstmann et al found that 
the complement regulatory protein factor H bound to 
the C-repeat region of the M protein mo1ecule.22 These 
investigators suggested that binding of factor H might 
prevent deposition of C3b on the bacterial surface by 
inhibiting activation of the alternative pathway of com- 
plement.‘* However, recently, Perez-Casal and co-workers 
constructed a mutant strain expressing an M protein in 
which the C-repeat region was deleted.23 The mutant M 
protein no longer bound factor H, as predicted, but the 
strain remained resistant to phagocytosis, indicating that 
some other mechanism, independent of factor H, must 
be involved. The other proposed antiphagocytic mecha- 
nism is based on the observation that incubation of GAS 
in plasma results in binding of fibrinogen to M protein 
Variable amino 






Factor H binding site 
Figure 2. Schematic diagram of the M-protein molecule, a dimeric, 
coiled-coil structure with its carboxy terminus anchored in the bacte- 
rial cell wall. 
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on the bacterial surface.24,25 Coating of the bacteria with 
fibrinogen is associated with reduced deposition of C3b 
and resistance to phagocytosis. Although this mechanism 
may be operative for some strains, recent work by Dale 
and colleagues showed that type 18 M protein binds fib- 
rinogen very poorly, although type 18 strains are resistant 
to phagocytosis. 26 These results indicate that M proteins 
vary not only in their antigenic determinants, but also in 
their functional properties. 
The M-protein story turns out to be even more com- 
plex. Recent studies by a number of investigators have 
demonstrated that many if not most strains of GAS con- 
tain one or two additional genes encoding distinct surface 
proteins closely related in structure to M protein.27-29 The 
genes encoding M and M-related proteins are arranged 
in tandem on the GAS chromosome in a locus that is 
flanked on one side by the scpA gene encoding the strep 
tococcal C5a peptidase (Figure 3). Cleary and co-work- 
ers have shown that this protease degrades the 
chemotactic complement fragment C5a, thereby reduc- 
ing migration of neutrophils into the site of tissue infec- 
tion.30,31 On the other side of the M-protein gene cluster 
is a gene previously known as mry or virR and now 
called mga, for multigene activator. The mga gene 
encodes a trans-acting regulatory protein the synthesis 
of which is upregulated in response to environmental 
signals. 32-34 The mga gene product binds to the promoter 
region upstream of each of the M-related protein genes 
and the C5a peptidase gene, dramatically increasing gene 
expression.35 Thus, the mga regulon represents a genetic 
mechanism through which multiple virulence determi- 
nants are coordinately regulated in response to environ- 
mental cues, helping the organism to adapt to different 
environments within the host. 
In addition to M protein itself, the M-related proteins 
have a potential role in pathogenesis. Studies from sev- 
eral laboratories have shown that the M-related proteins 
may bind human plasma proteins including IgG, IgA, fib- 
rinogen, and the classic complement pathway regulatory 
protein, C4-binding protein. 36-39 Non-opsonic binding of 
the Fc portion of IgG or IgA by GAS surface proteins may 
interfere with phagocytosis by effectively inactivating 
potentially opsonic antibodies. Binding of fibrinogen or 
C4-binding protein to the bacterial surface may inhibit 
deposition of opsonic complement proteins, particularly 
mga: multi- 
gene activator 
emm, enn, fcr, mrp, arp, sir, etc: 1 to 3 
related genes encoding M or M-like proteins 
Figure 3. The M-protein gene family: 1 to 3 genes encoding struc- 
turally related proteins are arranged in tandem on the group A strep- 
tococcal chromosome in a locus flanked by the mga and scpA genes. 
C3b. The functional importance of M-related proteins 
was supported by recent work of Podbielski and co-work- 
ers, who showed that mutations in the M-related pro- 
teins impaired the capacity of GAS to grow in human 
blood, implying that these proteins, like M protein itself, 
play a role in resistance to phagocytosis.40 
DISSEMINATION OF VIRULENT STRAINS AS 
A CAUSE OF INCREASED INVASIVE DISEASE 
Given the diversity of structure and function of the M 
and M-related proteins, it is not surprising that GAS of cer- 
tain M-protein types, especially Ml and M3, are particu- 
larly strongly associated with invasive infections.41-43 One 
hypothesis to explain the recent increase in invasive infec- 
tions is wider dissemination of these virulent serotypes. 
Schwartz et al analyzed the prevalence of M types among 
GAS clinical isolates submitted to the reference laboratory 
of the US Centers for Disease Control and Prevention 
during the 1970s and 198Os.** The proportion of isolates 
represented by the Ml and M3 serotypes approximately 
doubled during the 1980s over figures for the 1970s 
while the prevalence of less invasive serotypes stayed 
the same or decreased. These results are consistent with 
the hypothesis that the rising incidence of invasive infec- 
tions is a result of increased prevalence of virulent 
serotypes in the population. 
Is there something about the Ml and M3 strains that 
makes them more likely to cause invasive disease? In a 
study of serotype Ml clinical isolates, Cleary and col- 
leagues found that the chromosomal DNA of nearly all the 
isolates associated with invasive infection had a distinc- 
tive restriction-fragment profile and that all of these 
strains contained the gene for streptococcal pyrogenic 
exotoxin A (SPE A).45 Other studies of genetic related- 
ness among invasive disease isolates by Musser et al pro- 
vided evidence for global dissemination of a few virulent 
GAS strains.46z47 These results suggested that (1) many 
cases of invasive infection were caused by closely related 
strains and (2) SPE A itself might play a role in disease. 
STREPTOCOCCAL PYROGENIC EXOTOXINS AND 
STREPTOCOCCAL TOXIC SHOCK SYNDROME 
Streptococcal pyrogenic exotoxin A is one of at least 
three pyrogenic exotoxins produced by GAS. These tox- 
ins cause the rash of scarlet fever and were known pre- 
viously as erythrogenic or scarlet fever toxins. The genes 
for SPE A and SPE C are carried by bacteriophages, which 
provide a mechanism for transfer of the trait to other 
strains.48~49 The SPE B protein is also known as the strep- 
tococcal cysteine proteinase, a protease that has been 
shown to cleave interleukin 1B precursor to its active 
form, perhaps contributing to virulence.5o Several stud- 
ies have shown an association between strains producing 
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pyrogenic exotoxins, particularly SPE A, and streptococ- 
cal TSS.11-13,42 
The pyrogenic exotoxins belong to a family of pro- 
teins termed superantigens because they have the capac- 
ity to bind to and stimulate T cells that express particular 
VP elements of the T-cell receptor.51*52 A conventional 
antigen is recognized by a highly specific interaction 
between the hypervariable portion of the T-cell receptor 
and the antigen in the context of a major histocompati- 
bility complex (MHC) class II molecule on an antigen- 
presenting cell. Since very few T cells have the correct 
specificity, very few T cells bind to a given antigen. A 
superantigen bypasses this conventional antigen recog- 
nition pathway by binding directly to the VP element of 
the T-cell receptor and to the MHC molecule on the anti- 
gen-presenting cell. Because there are only a limited mm- 
ber of VP elements, a single superantigen may bind to 
and stimulate as many as 20% of circulating T cells. 
The potential consequences of a superantigen bind- 
ing to T cells include expansion of large subpopulations 
of T cells (or depletion through induction of apoptosis), 
increased production of inflammatory cytokines, and the 
physiologic effects of cytokines including fever, hypoten- 
sion, and increased vascular permeability (Table 4). Thus, 
many of the systemic manifestations of streptococcal TSS 
could reflect the superantigen activity of the pyrogenic 
exotoxins, although it remains to be proven that the phys- 
iologic effects of SPE A and other streptococcal toxins are 
consequences of toxin binding to and stimulation of 
T cells. 
NEW APPROACHES TO TREATMENT OF INVASIVE 
GROUP A STREPTOCOCCAL DISEASE 
Recognition of the possible pathogenic role of strepto- 
coccal toxins has led to consideration of new modes of 
therapy for patients with invasive GAS disease. Many clini- 
cians have noted the disappointing response of these 
patients to penicillin treatment, despite the continued in 
vitro susceptibility of GAS to penicillin. Eagle studied this 
phenomenon in the 1950s in a mouse model of strepto- 
coccal myositis. 53 He observed that penicillin treatment 
was ineffective if the animals were challenged with a 
large inoculum or if treatment was delayed.53 Eagle sug- 
gested that once the bacteria had grown to a high den- 
sity, their growth rate slowed so that they remained 
viable, but rarely divided. Since penicillin acts on cell 
wall synthesis, such “stationary phase” cells are resistant 
to killing by penicillin. 
More recently, these studies were extended by 
Stevens and co-workers, who confirmed the poor survival 
of mice treated with penicillin, particularly if treatment 
was delayed for 2 hours or longer.54 However, clindamycin 
was highly effective in this model, presumably because its 
mode of action is to bind to the ribosome and to inhibit 
Table 4. Potential Consequences of T-Cell Activation by a 
Superantigen 
Expansion (or depletion) of T-cell subpopulations 
Increased production of cytokines (IL-2, TNF, IFN-?I , others) 
Physiologic effects of cytokines: fever, hypotension, increased 
vascular permeability 
IL-2 = interleukin-2; TNF = tumor necrosis factor; IFN-y = interferon-y. 
protein synthesis, independent of the growth phase of 
the bacteria. On the basis of these experimental findings, 
a number of clinicians have begun to use clindamycin to 
treat patients with invasive GAS disease in the hope of 
more rapid bacterial killing and an immediate effect on 
exoprotein synthesis. 
The other mode of therapy under study is intra- 
venous immunoglobulin (IVIG), as pools of human 
immunoglobulin are likely to contain antibodies to the 
streptococcal toxins that may neutralize the systemic 
effects of the toxins. Norrby-Teglund et al collected 
plasma samples from a group of patients with strepto- 
coccal TSS who were treated with MG.55 The investiga- 
tors showed that stimulation of T cells by streptococcal 
culture supernatants could be inhibited by MG itself or 
by the patients’ plasma after MG infusion, although the 
same patients’ plasma before MG infusion was ineffec- 
tive. These data and encouraging preliminary results of 
a small case-control study support the use of MG in 
patients with streptococcal TSS.56 However, a random- 
ized, controlled, multicenter trial is necessary to deter- 
mine with any reasonable degree of certainty whether 
treatment with either clindamycin or MG improves the 
outcome of invasive GAS disease. 
HYALURONIC ACID CAPSULE 
AS A VIRULENCE FACTOR 
In contrast to capsular polysaccharides of many other 
encapsulated bacteria, that of GAS occurs in just one 
form. It is comprised of hyaluronic acid, a high-molecu- 
lar-weight linear polymer of alternating residues of N- 
acetylglucosamine and glucuronic acid. The GAS capsular 
polysaccharide is a very poor immunogen, presumably 
because it is seen by the immune system as a self-antigen 
that is identical to the hyaluronic acid in mammalian con- 
nective tissues5’ Certain strains of GAS produce large 
amounts of hyaluronic acid capsule, which imparts a dis- 
tinctive mucoid appearance to the colonies.58 
Clinical epidemiologic observations have suggested 
that such highly encapsulated strains are associated with 
serious GAS disease. For example, in a group of isolates 
collected in the United States during 1988-1990, 3% of 
isolates associated with uncomplicated pharyngitis were 
mucoid, whereas 21% of isolates from patients with 
invasive infections and 42% of rheumatic fever isolates 
were mucoid.*l 
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To study directly the role of the capsule in virulence, 
we derived unencapsulated mutants by transposon muta- 
genesis from a mucoid wild-type strain of GAS. In contrast 
to the encapsulated wild-type strain, the unencapsulated 
mutants were no longer resistant to complement-depen- 
dent phagocytosis by human neutrophils and were loo-fold 
less virulent in mice after intraperitoneal challenge.j9z60 
These results established that the hyaluronic acid capsule 
plays an important role in virulence. 
Perhaps more interesting were the results of pha- 
ryngeal colonization studies in mice.61 After inoculation 
with the encapsulated wild-type strain, about 60% of the 
mice developed positive throat cultures, which remained 
positive for 9 days. Several mice eventually developed 
systemic GAS infection and died. In contrast, none of the 
mice challenged with the unencapsulated strain died, 
fewer than one-third had positive throat cultures 1 day 
after inoculation, and even in these cases the organisms 
were cleared rapidly. These results indicate that the 
hyaluronic acid capsule confers a powerful survival advan- 
tage on GAS in the pharynx. In addition, these findings 
may explain, in part, the association between mucoid or 
highly encapsulated strains of GAS and ARl$ since ARF 
develops only in patients in whom pharyngeal infection 
persists for at least 9 days. 
CONCLUSIONS 
Serious GAS disease syndromes are certainly not new, 
but they appear to have become more common in the 
past decade. The changing spectrum of disease has been 
accompanied by an increased prevalence of strains with 
specific features implicated in virulence. Among the 
tremendously varied members of the M-protein family, M 
proteins 1 and 3 are particularly strongly associated with 
invasive infections, especially necrotizing fasciitis. Pyro- 
genie exotoxins, especially SPE A, appear to play a path- 
ogenic role in streptococcal TSS, perhaps through their 
activity as superantigens. Mucoid or highly encapsulated 
strains are associated with invasive infections and par- 
ticularly with rheumatic fever, a situation in which the 
capsule may enhance virulence by promoting persistence 
of the organism in the pharynx. 
The studies mentioned, along with many others not 
discussed, have given us new insights into the patho- 
genesis of streptococcal disease and have suggested new 
strategies for intervention. Careful analysis of these stud- 
ies, however, reveals not only associations between spe- 
cific bacterial virulence factors and certain disease 
syndromes, but also the complexity of the interactions of 
these bacterial traits and the immune effecters of the 
human host. The relative importance of several strepto- 
coccal products, either directly or as markers of virulent 
strains, has been discussed in this article. Nevertheless, 
no single streptococcal trait or product explains the vir- 
ulence of GAS; rather, streptococcal disease is a result of 
tipping the tenuous balance between the parasite and 
the host and depends upon the combined effects of a 
panoply of factors. Although we have some new clues to 
pathogenesis, streptococcal disease remains in many ways 
an unsolved mystery and a continuing challenge for 
researchers and clinicians. 
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